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Abstract
Background: Glucocorticoids (GCs), such as prednisone, are the standard of care for several inflammatory and
immunologically mediated diseases, but their chronic systemic administration is severely limited by serious adverse
effects that are both dose and time dependent. Short-term treatment (7–14 days) with oral prednisone is used for
many acute inflammatory and allergic conditions. This study was conducted to characterize the safety and
pharmacodynamic (PD) dose–response of a 7-day course of oral prednisone on biomarkers of GC receptor agonism.
Methods: In this randomized, single-blind, placebo-controlled, crossover study (A9001309), 37 healthy subjects
received placebo or a prednisone dose from 2.5–60 mg daily over 7 days in each of three treatment periods. White
blood cell counts and plasma samples for measuring cortisol, osteocalcin and procollagen type 1 N-propeptide (P1NP)
were obtained at 2, 4, 8, and 12 h post-dose on Day 1, immediately prior to dosing on Days 1, 2, and 4, and at nominal
dosing time on Days 0 and 8. Urine samples for urinary N-terminal cross-linked telopeptide of type 1 collagen
(uNTX) were collected on Days 0, 1, 2, 4, and 8. Serum samples for adiponectin were obtained prior to dosing
on days 0, 1, 4 and 8.
Results: Daily doses of prednisone up to 60 mg resulted in dose- and time-dependent decreases in plasma osteocalcin,
plasma P1NP, serum cortisol, and absolute blood eosinophil counts. Absolute blood neutrophil counts increased, while
blood lymphocyte counts rebounded to an increased level following an initial rapid decrease after dosing. An increase
was observed for uNTX and adiponectin. The incidence of adverse effects with prednisone was not dose related, and
nervous system disorders, mainly headache, were the most frequently reported adverse effects.
Conclusions: This characterization provides important and relevant information on safety and PD responses of
short-term prednisone dosing over the commonly-used clinical dose range, and also provides a reference for
early clinical development of dissociated agents targeting a differentiated PD profile.
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Background
Glucocorticoids (GCs) are commonly used to manage
inflammatory and immunologically-mediated condi-
tions [1–3], and continue to have a prominent place
in the clinic despite having a profile of serious ad-
verse effects that are dose- and time-dependent [4, 5].
Due to these known serious adverse effects, a GC
such as prednisone is used at the lowest effective
dose (5–7.5 mg daily) for chronic conditions such as
rheumatoid arthritis (RA); the use of higher doses is
limited to the shortest treatment duration required
for management of acute conditions and disease exac-
erbations [6, 7]. One of the most prevalent adverse
effects is that on bone remodeling, specifically, an un-
coupling of bone formation and resorption in favor of
bone loss via direct effects on osteoblasts [8]. Indeed,
the most common form of iatrogenic osteoporosis is
GC induced [9]. Many other adverse effects, such as
electrolyte imbalance, weight gain, and metabolic distur-
bances, result from GC-induced effects on other tissues
including the hypothalamic-pituitary-adrenal (HPA) axis
[10, 11]. Similarly, due to a plethora of effects on leuko-
cytes and vascular endothelial cells, such as altered cell
distribution patterns, immobilization, and apoptosis, GC
therapy can result in dramatic changes in circulating white
blood cell profiles that may contribute to an increased risk
of GC-associated infection [12–14].
Recent drug discovery and development efforts have
focused on approaches to reduce adverse effects, while
maintaining efficacy of GC therapy. These approaches
include development of a modified-release prednisone
formulation and discovery of selective GC receptor
ligands that putatively dissociate anti-inflammatory
effects mediated by genomic transrepression from
adverse effects mediated by genomic transactivation
[7, 15–18]. Despite the present understanding of the
known adverse effects of GC therapy, and recent
drug development efforts to potentially dissociate ef-
ficacy and safety of GCs, the dose–response and
time course of the effect of current GCs on various
biomarkers of GC receptor agonism (anti-inflamma-
tory and adverse effects) have not been systematically
characterized. The characterization of the safety and
pharmacodynamics (PD) of multiple doses of a
standard GC such as prednisone, over the commonly
used clinical dose range (2.5–60 mg once daily), pro-
vides important and relevant information for clinical
use, as well as reference for early clinical develop-
ment of dissociated agents targeting a differentiated
PD profile.
The present study was conducted to further characterize
the safety and dose–response of 7-day prednisone admin-




Eligible subjects were healthy adult volunteers aged 18–55
years (male) or 18–44 years (female), with a body mass
index of 18–30 kg/m2 and a total body weight >50 kg
(110 lb). Subjects with evidence or history of clinically
significant hematologic, renal, endocrine, pulmonary,
gastrointestinal, cardiovascular, hepatic, psychiatric,
neurologic, or allergic disease (including drug allergies,
but excluding untreated, asymptomatic seasonal allergies
at time of dosing) or any condition possibly affecting drug
absorption were excluded from the study.
Study design
This randomized, single-blind, placebo-controlled, cross-
over study (A9001309) was designed to characterize the
dose–response of prednisone on biomarkers of GC recep-
tor agonism. Within 28 days of screening, all eligible
subjects were randomly assigned to one of seven treat-
ment sequences, each with three 7-day treatment periods
separated by a 14-day washout period (Table 1). The
treatments in each sequence included either three of the
six prednisone doses evaluated in the study (2.5, 5, 10, 20,
40, or 60 mg), or two prednisone doses and placebo. In
the first treatment period only, all subjects had baseline
assessments on Day 0, the day prior to dosing.
Biomarker evaluations and analytic methods
HPA axis
Serum samples for morning cortisol were obtained
immediately prior to dosing or nominal dosing time on
Day 0 (baseline, day prior to first dosing) and on Days 1
(first day of dosing), 2, 4, and 8, in each of the three 7-day
treatment periods. Serum samples for cortisol were
obtained at 2, 4, 8, and 12 h following the first sample on
Day 0 (Period 1 only) and following the first prednisone
dose on Day 1. A radioimmunoassay (Roche Diagnostics,







A 5 Placebo 2.5 mg 10 mg
B 5 2.5 mg 5 mg 20 mg
C 5 5 mg 10 mg 40 mg
D 5 10 mg 20 mg 60 mg
E 5 20 mg 40 mg Placebo
F 5 40 mg 60 mg 2.5 mg
G 5 60 mg Placebo 5 mg
Total 35a
Doses shown correspond to the daily prednisone dose administered for 7 days
in each treatment period
aTwo subjects discontinued the study during Period 2 and were replaced
following approval by the study statistician
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Indianapolis, IN) was used initially for measurement of
cortisol in serum, but the results indicated the possibility
of assay interference from prednisone and its metabolite
prednisolone. Consequently, a specific, validated, high-
performance liquid chromatography assay (calibration
range, 10–3000 ng/mL) with tandem mass spectrometry
(SGS Cephac, Poitiers, France) was used to assay cortisol
in plasma samples collected for osteocalcin (OC) meas-
urement on Day 0 and Day 1 (pre-dose and 2, 4, 8, and
12 h post-dose) and prior to dosing on Day 2. These
plasma samples were stored at −70 °C until assayed for
cortisol and had previously undergone one freeze-thaw
cycle. Stability of cortisol was confirmed in plasma for a
time period greater than the duration of storage with up
to three freeze-thaw cycles.
Serum was also obtained for assaying cortisol levels on
Day 8 before and 30 min after low-dose adrenocortico-
tropic hormone (ACTH) stimulation. Subjects with an
abnormal low-dose ACTH stimulation response on Day
8 were administered the test again after 2 weeks. A
radioimmunoassay was used for measurement of serum
cortisol from the low-dose ACTH stimulation test. Assay
interference from prednisone and prednisolone was con-
sidered unlikely, since complete washout of both moieties
was expected at the time these samples were obtained.
White blood cell counts
Complete blood count with differential (data for neu-
trophils, eosinophils, and lymphocytes are shown) was
obtained at 2, 4, 8, and 12 h post-dose on Day 1, im-
mediately prior to dosing on Days 1, 2, and 4, and at
nominal dosing time on Days 0 and 8.
Bone metabolism
Plasma samples for OC, a biomarker of bone formation,
were collected serially on Day 0 (at nominal dosing time
and 2, 4, 8, and 12 h thereafter) and serially post-dose
on Day 1 (2, 4, 8, and 12 h), immediately prior to dosing
on Days 1, 2, and 4, and at nominal dosing time on Day
8; plasma samples for procollagen type 1 N-propeptide
(P1NP), also a bone formation marker, were collected
12 h post-dose on Day 1, immediately prior to dosing on
Days 2 and 4, and on Days 0 and 8. Urine samples for
urinary N-terminal cross-linked telopeptide of type 1
collagen (uNTX), a biomarker of bone resorption, were
collected from the second pre-noon voiding of the bladder
on Days 0, 1, 2, 4, and 8. OC and uNTX were assayed
using an enzyme-linked immunosorbent assay method.
P1NP was assayed by a validated radioimmunoassay. A
kinetic modification of the Jaffe reaction was used for the
quantitative measurement of urinary creatinine (uCr).
Pacific Biometrics, Inc. (Seattle, WA, USA) kits were used
for all four analytes.
Carbohydrate and metabolic effects
Serum samples for fasting glucose and insulin were
obtained immediately prior to dosing on Days 0, 1, 2, 4, 6,
and 7. For the oral glucose tolerance test (OGTT), the
subjects were to ingest 75 g of a glucose solution within
5 min of receiving study medication on Day 6; this solu-
tion was to be ingested within 10 min, and blood samples
for glucose were then collected at 0.5, 1, and 2 h. Serum
samples for triglycerides were obtained immediately prior
to dosing on Days 0, 1 and 4, and on Day 8 and, for adipo-
nectin, immediately prior to dosing on Days 0, 1 and 4,
and on Day 8. Serum samples were analyzed for adiponec-
tin using a LINCO Diagnostics Services (St. Charles, MO,
USA) radioimmunoassay; the validated range of the assay
was 2–100 ng/mL.
Central nervous system
Subjects were required to complete Profile of Mood
State (POMS™) and Medical Outcomes Study: Sleep
Scale (MOS-Sleep) questionnaires on the evening of
Days 0 and 7.
Safety
Adverse events (AEs) were monitored throughout, and
vital signs (sitting blood pressure and pulse rate) were
performed at screening and prior to dosing on Days 0, 1,
4, and 8; laboratory safety tests (hematology, blood
chemistry, urinalysis, and hormone and chronic infec-
tion tests), were performed at screening and on Day 0; a
post-void weight was taken at screening and on Days 1
and 8 of each treatment period.
Statistical analyses
The change from baseline in primary biomarker endpoints
(biomarkers of AEs and biomarkers of anti-inflammatory
activity) for each prednisone dose was compared with the
change from baseline for placebo, using a repeated-
measures crossover analysis of covariance model contain-
ing effects for sequence, period, time, dose, time by dose
interaction, and subject within sequence (as random
effect), as well as baseline as a covariate. For comparison
with placebo, the least squares mean difference, standard
error, 95 % confidence interval, and P value were reported.
Results
Subjects
Overall, 37 subjects were screened; all were assigned to
study treatment. Five subjects were assigned to each of
the seven treatment sequences (A-G) and received either
three active doses of prednisone 2.5, 5, 10, 20, 40, or
60 mg, or two active doses and placebo. Ultimately, each
of the treatments was received by 15 or 16 subjects. The
proportion of subjects completing the study was 91.9 %.
Two subjects in treatment sequence E (prednisone
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20 mg, 40 mg, and placebo in Periods 1, 2, and 3,
respectively) and one subject in treatment sequence G
(prednisone 60 mg, placebo, and prednisone 5 mg in
periods 1, 2, and 3, respectively) discontinued from the
study. The subject in treatment sequence G discontin-
ued during Period 2 while receiving placebo due to AEs
related to the study treatment. The other two subjects
discontinued from the study for reasons not related to
study treatment; both subjects withdrew consent. One
subject in treatment sequence E was also discontinued
during Period 2 while receiving prednisone 40 mg; both
subjects that discontinued during Period 2 were replaced
following approval by the study statistician. The other
subject in treatment sequence E was in treatment period
1 at discontinuation, and was not replaced.
Baseline characteristics
Demographic characteristics were similar among the
treatment groups. Subjects were aged between 18 and
50 years, and the majority were white and male (Table 2).
Effect of prednisone on markers of safety and efficacy
HPA axis
Plasma cortisol concentrations decreased rapidly follow-
ing the first dose of prednisone, and then recovered in a
dose-dependent manner (Fig. 1). Following single pred-
nisone doses of 20 mg and higher, all individual cortisol
measurements at 8 and 12 h post-dose were below the
lower limit of quantification (10 ng/mL), and mean pre-
dose cortisol concentrations in these dose groups on
Day 2 were lower than the corresponding median values
on Day 1 (baseline).
A low-dose ACTH stimulation test was carried out after
completion of all treatment periods to assess whether each
subject’s HPA axis was adversely affected by prednisone. A
normal response to ACTH was defined as an increase in
serum cortisol to >18 μg/dL within 30 min of ACTH
injection. At the end of treatment, 19/37 subjects demon-
strated normal responses to ACTH, and 18 subjects had
abnormal responses (serum cortisol outside of normal
limits) (Table 3). The 18 subjects returned in 2 weeks, and
after a second low-dose stimulation test, 16/18 subjects
had normal responses. Two subjects required a third test
and one subject required a fourth test before their
responses returned to normal. The two subjects who did
not achieve a normal response within 2 weeks received
prednisone doses of either 40 mg or 60 mg in the last
treatment period.
White blood cell counts
Daily doses of prednisone up to 60 mg resulted in dose-
and time-dependent effects on white blood cell counts.
Eosinophil counts relative to placebo demonstrated acute
dose-dependent reductions on Day 1. A significant reduc-
tion versus placebo was observed as early as 2 h post-dose
with prednisone 60 mg (Fig. 2a). At 4 h reductions were
significant at all doses, and from 4–12 h counts relative to
placebo were relatively stable (Fig. 2a). Reductions in
eosinophil counts relative to placebo were seen at most
doses on Day 8 (Fig. 2b).
Prednisone induced increases in neutrophil counts
relative to placebo throughout Day 1, with significant
increases seen with doses ≥10 mg at 12 h post-dose
(Fig. 2c). Differences in neutrophil counts relative to
placebo were variable over the next 7 days: significant
increases were observed with higher doses on Days 2
and 8, whereas decreases, which were significant with
the lower doses, were seen on Day 4 (Fig. 2d).
Table 2 Demographic characteristics of all treatment groups
Characteristic Male Female Total
(n = 30) (n = 7) (N = 37)
Age, years
Mean (SD) 33.7 (9.8) 35.6 (6.7) 34.1 (9.2)
Range 18–50 27–43 18–50
Race, n
White 21 5 26
Black 7 1 8
Other 2 1 3
Weight, kg
Mean (SD) 81.3 (10.2) 74.4 (9.2) 80.0 (10.3)
Range 57.2–101.6 60.8–84.8 57.2–101.6
Height, cm
Mean (SD) 177.0 (6.7) 160.6 (4.7) 173.9 (9.1)
Range 164.0–188.0 153.7–167.0 153.7–188.0
SD standard deviation
Fig. 1 Mean serum cortisol concentrations up to 24 h following the
first daily dose of prednisone. Pretreatment cortisol concentrations
over 24 h were measured in all subjects the day prior to the first day
of dosing in Period 1
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As was observed with neutrophil counts, lymphocyte
counts demonstrated acute dose-dependent reductions
versus placebo on Day 1, with significant reductions
observed with all doses as early as 2 h post-dose (Fig. 2e).
Reductions in lymphocyte counts relative to placebo were
greatest with most doses at 4 h post-dose, and were similar
to placebo with the lower doses at 12 h post-dose (Fig. 2e).
Lymphocyte counts relative to placebo continued to rise
over the treatment period, and significant increases were
seen with prednisone doses ≥10 mg on Day 8 (Fig. 2f).
Bone metabolism
Daily doses of prednisone up to 60 mg resulted in dose-
and time-dependent effects on biomarkers of bone metab-
olism. OC and P1NP are biomarkers of bone formation.
On Day 1, plasma OC significantly decreased relative to
placebo as early as 2 h post-dose, and continued to
decrease in a dose-dependent manner until 12 h post-dose
(Fig. 3a). Reductions in plasma OC relative to placebo
were significant for doses ≥5 mg on Day 2, and for all
doses on Day 8 (Fig. 3b). P1NP was significantly reduced
versus placebo with prednisone doses ≥20 mg on Day 1
(Fig. 3c). P1NP levels increased slightly relative to placebo
on Day 2, and then decreased in a dose- and time-
dependent manner until Day 8 (Fig. 3c).
Urinary NTX is a biomarker of bone loss. A significant
increase in uNTX normalized for uCr (uNTX/uCr)
versus placebo was observed with prednisone 60 mg by
Day 2, and further dose-dependent increases occurred
from Days 4–8 (Fig. 3d).
Metabolism
The results for fasting glucose and insulin on Days 1 and
8 are shown in Table 4. Differences in serum glucose
concentrations between prednisone and placebo were
small but significantly lower with prednisone 5 mg and
doses ≥20 mg on Day 4, and doses ≥40 mg on Days 7 and
8. The effect of prednisone on glucose metabolism was
tested using an OGTT on Day 6. Increases from baseline
in both glucose and insulin concentrations at 0.5 h were
observed for all prednisone doses and for placebo,
followed by steady decreases for all prednisone doses at 1
and 2 h. After 6 days of prednisone treatment, the changes
from baseline in both glucose and insulin concentrations
relative to placebo were not significant at most time
points (data not shown).
The effect of prednisone relative to placebo on serum
triglyceride levels was variable. On Day 1, prednisone
20 mg and 40 mg significantly raised triglyceride levels. On
Day 8, prednisone raised triglyceride levels, but the rela-
tionship to dose was inconsistent, and the impact generally
was not significant (Table 4). Dose- and time-dependent
effects of prednisone on adiponectin were also observed
relative to placebo. On Day 8, adiponectin was significantly
increased with higher prednisone doses (Table 4).
Central nervous system
The results of both the POMS™ and MOS-Sleep assess-
ments did not show any changes when comparing the
values to normative samples. However, no clear pattern
for the treatment arms appeared in either assessment.
Safety
There were no serious adverse events (SAEs) or deaths
reported. There were no clinically significant changes in
vital signs or body weight at any time point. The incidence
of AEs with prednisone was not dose related. Treatment-
emergent adverse events (TEAEs) were reported for two





Period Subjects with abnormal response to ACTH stimulation, n
1 2 3 Test 1 Test 2a Test 3b
(N = 37) (N = 18) (N = 2)
A 5 Placebo 2.5 mg 10 mg 3 0 0
B 5 2.5 mg 5 mg 20 mg 5 0 0
C 5 5 mg 10 mg 40 mg 4 1 1c
D 5 10 mg 20 mg 60 mg 5 1 0
E 6d 20 mg 40 mg Placebo 0 0 0
F 5 40 mg 60 mg 2.5 mg 0 0 0
G 6d 60 mg Placebo 5 mg 1 0 0
Total 37 18 2 1
Doses shown correspond to the daily prednisone dose administered for 7 days in each treatment period
ACTH adrenocorticotropic hormone
aSubjects who failed Test 1 were re-tested 2 weeks later
bSubjects who failed Test 2 were re-tested 2 weeks later
cReturned to normal on Study Day 138
dOne subject in sequence E and one in sequence G discontinued the study during Period 2 and were replaced following approval by the study statistician,
therefore n = 6 in these groups for this analysis
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to eight subjects (13–50 %) across the prednisone doses
and ten subjects (67 %) administered placebo. Central
nervous system disorders, mainly headache, were the most
frequently reported TEAEs (Table 5). Three subjects
reported severe AEs; all were headaches experienced while
on prednisone 2.5 mg, prednisone 20 mg, and placebo,
respectively; the headache in the subject dosed with
prednisone 2.5 mg was considered by the investigator to
be related to the study treatment.
Treatment-related AEs were reported by two subjects
(13 %) dosed with prednisone 2.5, 5, 20, and 40 mg,
respectively, no subjects dosed with 10 mg, and three
Fig. 2 Mean change from baseline (difference from placebo) in white blood cell counts. Eosinophil, neutrophil, and lymphocyte counts for Day 1
by hour (a, c, e) and for Days 1 through 8 (b, d, f) for each daily prednisone dose. *P ≤ 0.05 and **P ≤ 0.01 versus placebo
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Fig. 3 Mean change from baseline (difference from placebo) in biomarkers of bone metabolism. Change in osteocalcin (OC), procollagen type
1 N-propeptide (P1NP), and urinary N-terminal cross-linked telopeptide of type 1 collagen (uNTX) for each daily dose of prednisone. a OC: Day 1
by hour; (b) OC: Days 1–8; (c) P1NP: Days 1–8; (d) uNTX: Days 1–8. *P ≤ 0.05 and **P ≤ 0.01 versus placebo
Table 4 Mean differences from placebo (standard error) in fasting glucose, fasting insulin, triglycerides, and adiponectin
Parameter Day Prednisone (mg/day)
2.5 5 10 20 40 60
Fasting glucose, mg/dL 1 1.19 (1.97) 3.44 (1.97) 1.60 (1.97) 0.94 (1.96) 1.86 (1.99) 2.13 (1.93)
8 −2.06 (2.00) −1.40 (2.00) −2.11 (2.00) −3.24 (1.99) −6.66 (2.01)** −7.10 (1.97)**
Fasting insulin, μU/mL 1 2.15 (2.90) 2.24 (2.81) 1.69 (2.90) 2.10 (2.89) 1.21 (2.83) 1.76 (2.90)
8 −1.44 (2.34) −1.70 (2.34) −0.52 (2.34) −0.39 (2.32) −0.50 (2.34) 0.71 (2.31)
Triglycerides, mg/dL 1 39.19 (21.19) 17.93 (20.20) 22.60 (21.16) 85.79 (21.12)** 44.56 (20.52)* 37.18 (21.16)
8 5.43 (17.01) 13.56 (16.95) 8.82 (17.01) 9.66 (16.95) 35.59 (17.09)* 26.42 (16.76)
Adiponectin, μg/mL 1 −1.51 (0.69)* −1.61 (0.67)* −0.47 (0.69) −1.89 (0.69)* −0.73 (0.68) −0.18 (0.69)
8 −0.27 (0.58) −0.63 (0.58) 0.02 (0.58) 1.00 (0.58) 2.46 (0.58)** 2.47 (0.57)**
*P ≤ 0.05, **P ≤ 0.01 versus placebo
Fleishaker et al. BMC Musculoskeletal Disorders  (2016) 17:293 Page 7 of 10
subjects (19 %) dosed with 60 mg. Treatment-related
AEs were reported by four subjects (27 %) dosed with
placebo. Headache was the most frequently reported
treatment-related AE, occurring in one or two subjects
(6 % or 13 %) across the prednisone doses and one sub-
ject dosed with placebo.
Discussion
This study was designed to characterize the dose–response
and time course of prednisone effects on biomarkers of GC
receptor agonism in a healthy adult population over 7 days.
Daily doses of prednisone up to 60 mg were generally well-
tolerated and resulted in dose- and time-dependent effects
on a number of biomarkers. As would be expected, a de-
crease relative to placebo was noted in biomarkers of bone
formation (OC and P1NP), whereas there was an increase
in a biomarker of bone turnover (uNTX). Also as expected,
suppression of morning cortisol levels was seen at higher
prednisone doses. Metabolic effects on glucose concentra-
tions, OGTT, and triglyceride levels were modest and gen-
erally not statistically significant; however, adiponectin
levels were significantly increased relative to placebo with
higher prednisone doses by Day 8.
GCs are reasonably safe for short-term use. However,
serious complications have often been reported with
long-term use [10, 11]. In this study, inhibition of the
HPA axis was evident by the potent, dose-dependent
suppression of serum cortisol following the first dose of
prednisone. As expected, with regard to the low-dose
ACTH stimulation test, the subjects that took longer to
return to normal were in the treatment groups that
received the higher doses of prednisone in Period 3.
GCs are well known for their ability to affect circulating
white blood cell profiles. It is generally acknowledged that
administration of GC induces a transient fall in circulating
lymphocytes, which is maximal 4–6 h after administration
[19], particularly if the drug is administered in the morn-
ing [20]; this is thought to arise mainly from a reduced
efflux of lymphocytes from lymphoid organs [13]. The
transient fall is followed by a subsequent return to normal
values within 12–24 h [19]. This was demonstrated in the
present study, where all doses of prednisone reduced
lymphocyte counts within 2 h, with maximum effect seen
at 4–8 h. Levels started to return towards normal by 8 h
after dosing, and were close to baseline values by 24 h. Re-
peated dosing with prednisone resulted in dose-dependent
increases in lymphocyte counts, with the stimulation
maintained for doses ≥10 mg on Day 8. The increases in
lymphocyte count on the mornings prior to dosing were
likely due to a rebound phenomenon reported previously
for GCs [21]. Conversely, the dose-dependent decreases in
eosinophils observed in the first 24 h continued through
Day 8, albeit at a diminishing rate. The increased neutro-
phil counts observed following GC treatment are consist-
ent with the literature, and are thought to be due to
increased release from bone marrow and decreased
movement out of the blood into tissue sites [21, 22].
Osteoporosis, a condition characterized mainly by a
reduction in bone mineral density (BMD), is a well-
established side effect of chronic GC therapy. In fact,
Table 5 Treatment-emergent adverse events (all events that occurred in >1 subject)
TEAE TEAEs, n (%)
Prednisone (mg/day)
Placebo 2.5 5 10 20 40 60
(n = 15) (n = 15) (n = 15) (n = 15) (n = 16) (n = 15) (n = 16)
Total 10 (67) 6 (40) 5 (33) 2 (13) 8 (50) 3 (20) 4 (25)
Headache 4 (27) 4 (27) 1 (7) 0 4 (25) 2 (13) 3 (19)
Nasopharyngitis 1 (7) 0 2 (13) 1 (7) 0 0 1 (6)
Pharyngolaryngeal pain 0 1 (7) 1 (7) 0 1 (6) 1 (7) 0
Cough 0 0 1 (7) 1 (7) 1 (6) 0 0
Dyshidrosis 1 (7) 0 0 0 1 (6) 1 (7) 0
Dyspepsia 0 0 1 (7) 0 1 (6) 1 (7) 0
Abdominal pain, upper 0 1 (7) 0 0 0 0 1 (6)
Dermatitis, contact 0 1 (7) 1 (7) 0 0 0 0
Dizziness 1 (7) 0 0 0 0 0 1 (6)
Dysmenorrhea 0 0 0 0 1 (6) 0 1 (6)
Furuncle 1 (7) 0 1 (7) 0 0 0 0
Nausea 0 0 0 0 0 1 (7) 1 (6)
Pyrexia 1 (7) 0 1 (7) 0 0 0 0
TEAE treatment-emergent adverse event
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chronic use of GCs increases the already increased risk of
osteoporosis in patients with RA by twofold [23, 24].
Some studies suggest that the associated fractures actually
occur at higher BMD levels in patients treated with GCs
than in patients not treated with GCs [25]. However, low-
dose GC therapy has been recognized to avert the
deleterious effects of GCs seen at higher doses, possibly
due its anti-inflammatory effect countering the bone loss
caused by chronic inflammation; a literature review on the
safety of long-term, low-dose GC therapy in patients with
rheumatic diseases demonstrated that AEs can in fact be
quite modest [26]. For example, the data from four exten-
sively reviewed randomized controlled trials showed that
BMD loss over 2 years of low-dose prednisone treatment
is not significantly different from that with placebo. On
the other hand, osteoporosis is still likely to be the most
common side effect of chronic low-dose GC therapy [27].
Many studies maintain the idea that reduced bone
formation is predominantly responsible for the GC-
associated bone loss [28, 29]. OC, an osteoblast-derived
protein involved in bone formation, is routinely utilized
as a biomarker because of its close association with BMD
[30]. In this study, plasma OC levels were significantly
reduced as early as 2 h after the first administered pred-
nisone doses above 10 mg on Day 1. This decrease was
maintained throughout Day 1 and, consistent with the
literature [31, 32], throughout the treatment period. A
similar trend was also observed for P1NP, another
biomarker of bone formation. Furthermore, prednisone
increased uNTX, a biomarker of bone loss. Taken
together, these data support both decreased bone forma-
tion and increased resorption, and demonstrate dose- and
time-dependent effects of daily prednisone. Interestingly,
biomarkers of bone turnover are thought to be useful in
predicting the rate of bone loss in postmenopausal women
[33]. In addition, some of these biomarkers, such as
urinary C-telopeptide and free deoxypyridinoline, predict
the associated threat of hip fracture independently of
BMD [34], which is thought to be the most important pre-
dictor of osteoporotic fracture [35]. It has also been
reported that several of these markers, such as serum OC
and the CrossLaps peptide of urinary C-telopeptide, may
be used to monitor the efficacy of therapy in patients with
osteoporosis [36]. Furthermore, Garnero et al. reported
that the rate of bone turnover plays an increasing role as a
determinant of bone mass with increasing time following
menopause, with high bone turnover being associated
with low bone mass, and suggests that bone marker as-
sessment may be useful in the evaluation of osteoporosis
risk [37]. Thus, the bone biomarker data in the present
study have potential predictive value for subsequent bone-
related AEs of GCs.
This study carefully and thoroughly characterized the
dose–response of prednisone on two significant safety
concerns associated with use of GC: HPA axis suppression
and adverse effects on bone metabolism. The dose- and
time-dependent responses to prednisone on the HPA axis
and bone biomarkers can be used for comparison with
novel glucocorticoid receptor agonists. To demonstrate
preliminary evidence of dissociation, however, it is
essential to characterize dose–response for putative anti-
inflammatory biomarkers of GCs. In healthy volunteers
there is no ongoing inflammation that can be assessed for
evidence of dose-dependent suppression. The effects on
trafficking of circulating leukocytes may serve as a bio-
marker for anti-inflammatory effects in healthy volunteers.
While not true anti-inflammatory biomarkers, they are
likely to be associated with similar GC agonistic effects.
Conclusions
This characterization of the dose–response of prednisone
on various biomarkers of GC agonism provides important
and relevant information on safety and PD responses
associated with short-term prednisone dosing over the
commonly used clinical dose range, and provides a refer-
ence for early clinical development of dissociated agents
targeting a differentiated PD profile.
Abbreviations
ACTH, adrenocorticotropic hormone; AE, adverse event; BMD, bone
mineral density; DAGR, dissociated agonist of the glucocorticoid receptor;
GC, glucocorticoid; HPA, hypothalamic-pituitary-adrenal; MOS-Sleep, med-
ical outcomes study: sleep scale; OC, osteocalcin; OGTT, oral glucose toler-
ance test; P1NP, procollagen type 1 N-propeptide; PD, pharmacodynamics;
POMSTM, profile of mood state; RA, rheumatoid arthritis; TEAE, treatment-
emergent adverse event; uCR, urinary creatinine; uNTX, urinary N-terminal
cross-linked telopeptide of type 1 collagen
Acknowledgements
The authors would like to thank the A9001309 study team as well as
Charles Mebus, PhD, former DAGR Research Lead, Thomas C. Stock, DO,
former DAGR Clinical Lead. Pfizer personnel were involved in protocol
development, conducting the study, data analysis and interpretation, and
the decision to submit the manuscript for publication. Editorial support
was provided by Gary Dever, PhD, at Complete Medical Communications.
Funding
This study was sponsored by Pfizer Inc. Editorial support was provided by
Complete Medical Communications and was funded by Pfizer Inc.
Availability of data and materials
Original data sources supporting the results of this manuscript can be made
available on request from the corresponding author.
Authors’ contributions
DLF, AM, FSW, and BGZ contributed to study design, analysis, and
interpretation. SD participated in study conduct. All authors contributed to,
read, and approved the final manuscript.
Competing interests
DLF and AM are employees of Pfizer Inc and own stock in Pfizer Inc. FSW
and BGZ were employees of Pfizer at the time of the study, and FSW owns
stock in Pfizer Inc. SD and BGZ have no current financial interests to disclose.
Consent for publication
Not applicable.
Fleishaker et al. BMC Musculoskeletal Disorders  (2016) 17:293 Page 9 of 10
Ethics approval and consent to participate
The final protocol, any amendments, and informed consent documentation
were reviewed and approved by the Institutional Review Board of Jasper
Clinic, Inc. (Kalamazoo, MI, USA). All subjects provided written, informed
consent to participate in the study. The study was conducted in compliance
with the ethical principles originating in or derived from the Declaration of
Helsinki and in compliance with all International Conference on
Harmonisation Good Clinical Practice guidelines.
Author details
1Pfizer Inc, Eastern Point Rd, Groton, CT 06340, USA. 2Innovative Analytics,
161 East Michigan Ave, Kalamazoo, MI 49007, USA. 3Jasper Clinic Inc, 526
Jasper Street, Kalamazoo, MI, USA. 4Astellas Pharma Global Development,
Northbrook, IL 60062, USA.
Received: 4 December 2015 Accepted: 11 June 2016
References
1. Abroug F, Ouanes I, Abroug S, Dachraoui F, Abdallah SB, Hammouda Z,
Ouanes-Besbes L. Systemic corticosteroids in acute exacerbation of COPD: a
meta-analysis of controlled studies with emphasis on ICU patients. Ann
Intensive Care. 2014;4:32.
2. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination
therapy with beta-adrenergic agonists in airways disease: present and
future. Eur J Clin Pharmacol. 2009;65:853–71.
3. Morand EF. Effects of glucocorticoids on inflammation and arthritis. Curr
Opin Rheumatol. 2007;19:302–7.
4. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown
JP, Cohen A, Kim H. A practical guide to the monitoring and management
of the complications of systemic corticosteroid therapy. Allergy Asthma Clin
Immunol. 2013;9:30.
5. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-
associated adverse events. Curr Opin Rheumatol. 2008;20:131–7.
6. Engvall IL, Brismar K, Hafstrom I, Tengstrand B. Treatment with low-dose
prednisolone is associated with altered body composition but no difference
in bone mineral density in rheumatoid arthritis patients: a controlled cross-
sectional study. Scand J Rheumatol. 2011;40:161–8.
7. Krasselt M, Baerwald C. The current relevance and use of prednisone in
rheumatoid arthritis. Expert Rev Clin Immunol. 2014;10:557–71.
8. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-
induced bone loss in men. J Clin Endocrinol Metab. 1998;83:801–6.
9. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-
induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777–87.
10. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression
and recovery of adrenal response after short-term, high-dose glucocorticoid
treatment. Lancet. 2000;355:542–5.
11. Kirwan JR, Hickey SH, Hallgren R, Mielants H, Bjorck E, Persson T, Wollheim
FA. The effect of therapeutic glucocorticoids on the adrenal response in a
randomized controlled trial in patients with rheumatoid arthritis. Arthritis
Rheum. 2006;54:1415–21.
12. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious
infections in rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1157–60.
13. Bloemena E, Weinreich S, Schellekens PT. The influence of prednisolone on
the recirculation of peripheral blood lymphocytes in vivo. Clin Exp
Immunol. 1990;80:460–6.
14. Cavalcanti DM, Lotufo CM, Borelli P, Ferreira ZS, Markus RP, Farsky SH.
Endogenous glucocorticoids control neutrophil mobilization from bone
marrow to blood and tissues in non-inflammatory conditions. Br J
Pharmacol. 2007;152:1291–300.
15. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N,
Rehwinkel H, Hennekes H, Asadullah K. Dissociation of transactivation from
transrepression by a selective glucocorticoid receptor agonist leads to
separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A.
2004;101:227–32.
16. Stock T, Fleishaker D, Wang X, Mukherjee A, Mebus C. Phase 2 evaluation of
PF-04171327, a dissociated agonist of teh glucocorticoid receptor, for the
treatment of rheumatoid arthritis in patients with an inadequate response
to methotrexate. Arthritis Rheum. 2013;65 Suppl 10:2336.
17. Berlin M. Recent advances in the development of novel glucocorticoid
receptor modulators. Expert Opin Ther Pat. 2010;20:855–73.
18. Stock T, Fleishaker D, Mukherjee A, Le V, Xu J, Zeiher B. Evaluation of Safety,
Pharmacokinetics and Pharmacodynamics of a Selective Glucocorticoid
Receptor Modulator (SGRM) in Healthy Volunteers. Arthritis Rheum. 2009;60:
420.
19. Fauci AS, Dale DC. The effect of Hydrocortisone on the kinetics of normal
human lymphocytes. Blood. 1975;46:235–43.
20. Xu J, Winkler J, Sabarinath SN, Derendorf H. Assessment of the impact of
dosing time on the pharmacokinetics/pharmacodynamics of prednisolone.
AAPS J. 2008;10:331–41.
21. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency
evaluation of major corticosteroids: pharmacokinetics and cell trafficking
and cortisol dynamics. J Clin Pharmacol. 2003;43:1216–27.
22. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of
action and clinical considerations. Ann Intern Med. 1976;84:304–15.
23. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B,
Kohler JA, Furst DE. Low dose long-term corticosteroid therapy in rheumatoid
arthritis: an analysis of serious adverse events. Am J Med. 1994;96:115–23.
24. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids; a
systematic review of prospective studies in rheumatoid arthritis and other
diseases. J Rheumatol. 1997;24:1495–503.
25. Sambrook P, Lane NE. Corticosteroid osteoporosis. Best Pract Res Clin
Rheumatol. 2001;15:401–13.
26. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, de Koning EJ,
Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW. Safety of low dose
glucocorticoid treatment in rheumatoid arthritis: published evidence and
prospective trial data. Ann Rheum Dis. 2006;65:285–93.
27. Bouvard B, Legrand E, Audran M, Chappard D. Glucocorticoid-induced
osteoporosis: a review. Clin Rev Bone Miner Metab. 2010;8:15–26.
28. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in
postmenopausal women with rheumatoid arthritis. Effects of corticosteroids
and hormone replacement therapy. Arthritis Rheum. 1995;38:902–6.
29. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP. The course
of biochemical parameters of bone turnover during treatment with
corticosteroids. J Clin Endocrinol Metab. 1991;72:382–6.
30. Hari Kumar KV, Muthukrishnan J, Verma A, Modi KD. Correlation between
bone markers and bone mineral density in postmenopausal women with
osteoporosis. Endocr Pract. 2008;14:1102–7.
31. Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum
osteocalcin in healthy young men. J Bone Miner Res. 1988;3:113–5.
32. Lems WF, Jacobs JW, Van Rijn HJ, Bijlsma JW. Changes in calcium and bone
metabolism during treatment with low dose prednisone in young, healthy,
male volunteers. Clin Rheumatol. 1995;14:420–4.
33. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone
turnover predict postmenopausal forearm bone loss over 4 years: the
OFELY study. J Bone Miner Res. 1999;14:1614–21.
34. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C,
Cormier C, Breart G, Meunier PJ, Delmas PD. Markers of bone resorption
predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone
Miner Res. 1996;11:1531–8.
35. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant
HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction
of hip fractures. The Study of Osteoporotic Fractures Research Group.
Lancet. 1993;341:72–5.
36. Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R.
Prevention of early postmenopausal bone loss with cyclical etidronate
therapy (a double-blind, placebo-controlled study and 1-year follow-up).
J Clin Endocrinol Metab. 1997;82:2784–91.
37. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone
turnover in late postmenopausal women is a major determinant of
osteoporosis. J Bone Miner Res. 1996;11:337–49.
Fleishaker et al. BMC Musculoskeletal Disorders  (2016) 17:293 Page 10 of 10
